BCR and neutropenia: In cases of resistance or suboptimal response, as indicatedby persistent high BCR-ABL levels or hematologic abnormalities such as neutropenia and thrombocytopenia, treatment was escalated tosecond-generation TKIs like Nilotinib or Dasatinib.